trending Market Intelligence /marketintelligence/en/news-insights/trending/oYjj_mypLOb0gWUUHQOhig2 content esgSubNav
In This List

Theralase raises C$1.4M to fund bladder cancer therapy

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Theralase raises C$1.4M to fund bladder cancer therapy

Theralase Technologies Inc. closed a private placement of stock and warrant units to raise about C$1.4 million in gross proceeds, which will be used to develop a bladder cancer treatment.

The Toronto-based healthcare company sold 4,095,157 units priced at 35 Canadian cents apiece in the offering. Theralase Technologies will use the proceeds from the sale to develop its bladder cancer therapy as well as for working capital and general corporate purposes.

Each unit in the offering is made up of 1 common share of Theralase Technologies and a warrant to purchase 1 common share for 50 cents each within 24 months.

Theralase Technologies develops laser technology platforms to destroy cancer cells and treat other diseases.